EMEA-001555-PIP01-13-M03
Key facts
| Invented name |
Xerava
|
| Active substance |
eravacycline
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0251/2019
|
| PIP number |
EMEA-001555-PIP01-13-M03
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of complicated intra-abdominal infection
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Tetraphase Pharmaceuticals, Inc.
Tel. +1 617 7153600 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|